Loading
A next-generation pill that blocks only CDK4, not CDK6, to keep the benefit of today's drugs without the low blood counts.
Pfizer's CDK4-selective inhibitor. Phase 2 FOURLIGHT-1 (second line, with fulvestrant) positive in early 2026 with lower neutropenia than dual inhibitors; phase 3 FOURLIGHT-3 compares atirmociclib + letrozole with a CDK4/6 inhibitor + letrozole in first line. Rationale: CDK6 inhibition drives neutropenia while CDK4 carries most of the antitumour effect in luminal breast cancer.
ATP-competitive inhibitor selective for CDK4 over CDK6 (~70-fold). Connects to CDK4/6.
1.Cyclin D1-CDK4 phosphorylates RB in luminal breast cancer cells
Compare all products across the US, EU, UK, Japan, China and Australia →
Positive topline phase 2 FOURLIGHT-1 source
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Atirmociclib" OR ABSTRACT:"Atirmociclib" OR TITLE:"PF-07220060" OR ABSTRACT:"PF-07220060") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Atirmociclib, not a curated reading list.
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, CDK4/6, Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test, CDK4/6 inhibitors.
Shares A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer., Study of PF-07248144 in Advanced or Metastatic Solid Tumors, HR-positive metastatic breast cancer after CDK4/6 inhibitors, Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test.
Shares CDK4/6, Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test, CDK4/6 inhibitors, Pfizer (incl. Seagen).
Shares CDK4/6, Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test, CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer.
Shares Palazestrant combination study, Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease, CDK4-selective inhibitors as the new first-line backbone, The cell-cycle engine (cyclins & CDKs).
Shares Study of PF-07248144 in Advanced or Metastatic Solid Tumors, Pfizer (incl. Seagen), HR-positive / HER2-negative breast cancer.
Shares CDK4/6, Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test, CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer.
Shares The cell-cycle engine (cyclins & CDKs), CDK4/6, CDK4/6 inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/